Pharmaceuticals News

TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative...

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the...

Oslo, September 1, 2026: In connection with the Extraordinary General Meeting of Zelluna ASA to be held on September 9, 2026, Anders Tuv, Chair of the Board of Directors, has, as of the date of this...

Ingelheim, Germany, and Bracknell, United Kingdom SCOVELLA® is the first therapy specifically developed and approved for the treatment of hyperinsulinemia in insulin-dysregulated horses and ponies1,...

Company announcement no. 33 - 2601 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

MELBOURNE, Australia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated...

Resolution Therapeutics partners with the Blood Centers of America to support broad patient access to its experimental Regenerative Macrophage Therapy

COPENHAGEN, Denmark, September 1, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the new share buy-back program announced on August 21, under which the Company intends to...

KØBENHAVN, Danmark, 1. september 2026 – Bavarian Nordic A/S (OMX: BAVA) påbegynder i dag den første del af det nye aktietilbagekøbsprogram, der blev annonceret den 21. august, hvorunder selskabet vil...

Ad hoc announcement pursuant to Art. 53 LR    REMODEL-1/-2 trials met their primary endpoint, significantly reducing annualized relapse rate (ARR) vs teriflunomide in people living with relapsing...